Phacoemulsification combined with a new ab interno gel stent to treat open‐angle glaucoma: Pilot study. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Sheybani, Arsham; Lenzhofer, Markus; Hohensinn, Melchior; Reitsamer, Herbert; Ahmed, Iqbal Ike K.
• Is Part Of: Journal of cataract and refractive surgery. Volume 41:Issue 9(2015)
• Publication Date: 2015-09
• Subjects: 617.7
• DOI: 10.1016/j.jcrs.2015.01.019
• Languages: English
• ISSNs: 0886-3350

Abstract

Abstract : Purpose : To study the effect on intraocular pressure (IOP) of implanting a new gelatin stent at the time of cataract surgery in the treatment of open‐angle glaucoma (OAG). Setting : Multicenter university and private‐practice settings. Design : Nonrandomized prospective clinical trial. Methods : The implantation of 2 models of a gelatin stent (Xen140 and Xen63) was performed at the time of cataract surgery without mitomycin‐C. Complete success was defined as a postoperative IOP of less than 18 mm Hg and more than a 20% reduction in IOP at 12 months without glaucoma medication. Failure was defined as loss of light perception vision or worse, a need for additional glaucoma surgery, or less than a 20% reduction in the IOP from baseline. Results : The study included 37 eyes of 37 patients. The mean preoperative IOP was 22.4 mm Hg ± 4.2 (SD) on 2.5 ± 1.4 medication classes. Twelve months postoperatively, the mean IOP was reduced to 15.4 ± 3.0 mm Hg on 0.9 ± 1.0 medication classes ( P < .0001). This resulted in a qualified success of 85.3% and a complete success rate off medications of 47.1%. There were no failures. Conclusion : Cataract surgery combined with implantation of the gelatin stent resulted in a significant reduction in IOP in eyes with OAG. Financial Disclosure : Dr. Sheybani has received travel reimbursement from Aquesys, Inc. Dr. Ahmed is a paid consultant to Aquesys, Inc. No other author has a financial or proprietary interest in any material or method mentioned.